•   George Lundberg, MD

    This academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.

    .

  •   George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  •   George Lundberg, MD

    Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.

    .

    .

  •   George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  •   George Lundberg, MD

    On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

    .

  •   George Lundberg, MD

    This outline from the National Cancer Institute covers recent research on colorectal cancer.

    .

  •  

    What’s New in Melanoma Treatment in 2021?

    Emma Shtivelman, PhD

    I last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: NALIRIFOX, a combination of liposomal irinotecan (Onivyde) with fluorouracil (5-FU), leucovorin, and oxaliplatin is shown to be safe as a first line treatment in locally advanced or metastatic pancreatic cancer.

    .

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about Precision Promise, an adaptive multi-site clinical trial spearheaded by the Pancreatic Cancer Action Network.

    .

  •   Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.

    .